By Months: Irja Lutsar
Total Months: 17
Fully Profiled: 17
10.2025
7 Speeches
The speaker demonstrates expertise in the details of research and development funding, citing specific budget figures (80 million for the Ministry of Economic Affairs and Communications versus 1.48 million for the Ministry of Social Affairs). The role of clinical trials and their underfunding within the Ministry of Social Affairs budget is separately emphasized, demonstrating knowledge of the foundations of evidence-based treatment.
09.2025
6 Speeches
The speaker demonstrates strong expertise in the fields of crisis resolution (civil crisis) and medicine, claiming to have recently observed civil crisis management firsthand. They utilize specific knowledge, referencing the nature of medicine as an empirical discipline and the lengthy timelines required to obtain research permits (a year and a half). Furthermore, they are well-versed in the impact of data protection regulations on scientific research both in Estonia and across the wider European Union.
06.2025
10 Speeches
The speaker possesses deep expertise in the fields of medicine and healthcare, particularly concerning intensive care, end-of-life care, and infectious diseases (HIV). They utilize technical terminology (PET, positron emission tomography) and draw upon personal experience, having worked as a pediatrician and conducted studies at Tartu Prison. Furthermore, they demonstrate awareness regarding issues in legal education and the structure of healthcare provision within correctional facilities.
05.2025
1 Speeches
The speaker demonstrates expertise regarding the levels of the education system—basic, secondary (gymnasium), and higher education—as well as international study tracks. They employ a data-driven approach, noting the poor quality of the data, and validated their knowledge using artificial intelligence, which suggests strong technical awareness.
04.2025
13 Speeches
High level of expertise in the fields of medicine, pharmacy, and social policy, citing over 45 years of personal medical experience. Uses precise terminology (ethics committee, hospital exemption, palliative care) and demonstrates deep knowledge of the specifics of legislative amendments and committee deliberations. Is also aware of European Union directives and their transposition procedures.
03.2025
5 Speeches
The speaker demonstrates profound expertise in the fields of public health, pharmaceuticals, and scientific regulation, utilizing technical terminology (e.g., mRNA technology, validated laboratory tests). They support their arguments with specific data, referencing statistics from the Estonian State Agency of Medicines regarding adverse effects (0.2–0.3%) and the 2023 Nobel Prize. They emphasize the importance of scientific competence and the authority of the European Medicines Agency (EMA).
02.2025
2 Speeches
The speaker demonstrates profound expertise in the field of science and research management, identifying themselves as a former scientist. Specific terminology is employed, such as "grants," "uncertainty," and "data cross-utilization," which points to their authority on issues of science policy and data infrastructure. Particular emphasis is placed on the necessity of data preservation, analysis, and aggregation.
01.2025
11 Speeches
The speaker demonstrates profound expertise in medicine and the organization of healthcare systems, citing their specific field (medical science) and employing specialized terminology (consolidation, anesthesia services, depreciation/amortization). They emphasize the functional planning of services, for instance, highlighting the necessity of co-locating maternity care and surgical care, and referencing the development concept of the Tartu University Hospital. However, they acknowledge their lack of expertise in the construction sector.
12.2024
12 Speeches
The speaker exhibits profound expertise in pharmaceutical regulation and clinical trials, utilizing technical terminology (e.g., CAR-T therapy, hospital exemption, the Agency of Medicines, placebo). The analysis concerning amendments to the Medicines Act and the resulting safety risks is particularly detailed, citing examples of contamination-related adverse effects and referencing specific legal statutes. They are capable of presenting complex committee deliberations objectively, while simultaneously incorporating their own expert judgments.
11.2024
12 Speeches
The speaker demonstrates profound expertise in healthcare policy, referencing their background as a medical professional and utilizing technical terms such as "activity-based budget" and "metrics." They show detailed knowledge of the precise wording of draft legislation (e.g., Section 5, Subsection 1 of the Abortion Act) and the funding formulas used for local governments. Furthermore, they possess knowledge regarding the work processes and consensus decisions of the Social Affairs Committee.
10.2024
8 Speeches
The speaker demonstrates deep expertise in the social and healthcare sector, particularly concerning drug market regulation, supply shortages, and the financing of mental health services. Specific terminology is used (e.g., half-life, radiopharmaceuticals, co-payment, outpatient network), and extensive reference is made to commission discussions and ministry analyses. Data protection issues in social work are emphasized separately.
09.2024
4 Speeches
The speaker demonstrates expertise in national defense financing strategies and cyber threat assessment, stressing the potential for human casualties should systems fail. His/her knowledge is particularly thorough regarding the regulation of medical devices, where he/she references specific tools (insulin pumps, dosage calculators) and the specialized competence of institutions (the State Agency of Medicines), which is grounded in medical education.
06.2024
4 Speeches
The speaker demonstrates clear expertise in public health, medical education, and data management systems (registries). They cite 15 years of personal experience working with the HIV infection registry and are capable of analyzing complex ethical and legal issues related to the retrospective evaluation of COVID restrictions. They use technical terminology, such as "Public Health Emergency of International Concern," and refer to specific professional associations (the Estonian Society of Infertility Treatment and Embryology).
05.2024
7 Speeches
The speaker demonstrates deep expertise in the social sector and demography, using comparative examples (Austria, France, India) regarding the impact of birth rates and family benefits. The speaker is analytical on the topic of labor shortages, questioning the logic of the current situation and demanding data-driven analysis. Furthermore, the speaker relies on expert knowledge, proposing the creation of a scientific advisory council to solve the economic crisis.
04.2024
3 Speeches
The speaker demonstrates expertise in data management and regulatory obstacles, stressing that sufficient data has been collected, but the problem lies in its accessibility. They also possess knowledge of public health crisis management, specifically referencing the HIV and COVID-19 crises and the necessity for rapid and easily understandable health information. Their expertise focuses on the practical challenges inherent in policy implementation.
03.2024
4 Speeches
The speaker demonstrates profound expertise in healthcare policy and the structure of the medical system, focusing specifically on workforce shortages, the allocation of residency positions, and quality of care audits. They use specific terminology (e.g., general practitioners, remote consultations, evidence-based practice, hybrid work) and reference the positions of the National Audit Office and the Minister of Health. Their professional awareness also extends to topics such as pharmaceutical price negotiations and the historical conflict surrounding the role of pharmacies.
01.2024
9 Speeches
High authority and deep expertise are evident in the fields of science funding, scientist career models, and especially the regulation of medicine and vaccines. Technical terminology is utilized (e.g., genotoxic studies, blinded studies, core funding, knowledge transfer), and reference is made to international studies, data from the Agency of Medicines, and EU directives. The speaker is able to explain complex scientific and regulatory processes (e.g., why placebo groups are discontinued).